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Abstract: The current novel coronavirus disease (COVID-19) has spread globally within a matter
of months. The virus establishes a success in balancing its deadliness and contagiousness, and
causes substantial differences in susceptibility and disease progression in people of different ages,
genders and pre-existing comorbidities. These host factors are subjected to epigenetic regulation;
therefore, relevant analyses on some key genes underlying COVID-19 pathogenesis were performed
to longitudinally decipher their epigenetic correlation to COVID-19 susceptibility. The genes of
host angiotensin-converting enzyme 2 (ACE2, as the major virus receptor) and interleukin (IL)-6
(a key immuno-pathological factor triggering cytokine storm) were shown to evince active epige-
netic evolution via histone modification and cis/trans-factors interaction across different vertebrate
species. Extensive analyses revealed that ACE2 ad IL-6 genes are among a subset of non-canonical
interferon-stimulated genes (non-ISGs), which have been designated for their unconventional re-
sponses to interferons (IFNs) and inflammatory stimuli through an epigenetic cascade. Furthermore,
significantly higher positive histone modification markers and position weight matrix (PWM) scores
of key cis-elements corresponding to inflammatory and IFN signaling, were discovered in both ACE2
and IL6 gene promoters across representative COVID-19-susceptible species compared to unsuscep-
tible ones. The findings characterize ACE2 and IL-6 genes as non-ISGs that respond differently to
inflammatory and IFN signaling from the canonical ISGs. The epigenetic properties ACE2 and IL-6
genes may serve as biomarkers to longitudinally predict COVID-19 susceptibility in vertebrates and
partially explain COVID-19 inequality in people of different subgroups.
Keywords: COVID-19; angiotensin converting enzyme 2; interferons; IL-6; epigenetic regulation
1. Introduction
First identified in Wuhan, China, December 2019, the novel coronavirus disease 2019
(COVID-19) spread worldwide and caused over 0.68 million confirmed deaths and 17
million infected cases across 200 countries by the end of July 2020 [1,2]. COVID-19 stands
out as a new zoonotic disease caused by Severe Acute Respiratory Syndrome coronavirus
2 (SARS-CoV-2) [3], which, in the view of a virus, obtains an effective balance between
its deadliness and contagiousness in humans [4,5]. In line with that, patients with ages
over 45, especially 75 years old, had a worse prognosis and 5–10-fold higher mortality
rate than younger ones at 0–17 years old, who mostly showed a mild disease or even
asymptomatic [6–15]. Similarly, higher mortality rates were observed in males than females,
and particularly in the patients who have pre-existing medical conditions (comorbidities)
regardless of gender or age [6–15]. These underlying comorbidities include diabetes, cancer,
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immunodeficiency, hypertension and cardiovascular disease, asthma and lung disease,
kidney disease, as well as chronic gastrointestinal (GI)/liver disorders. In addition to
predictable symptoms of cough, fever and headache from the lung infection, the virus can
spread to almost every organ including the brain, heart, gut, kidneys, and skin to cause
organ-specific problems [6–15]. Therefore, on the host side, SARS-CoV-2 susceptibility
and disease progression of COVID-19 is a phenomenon of epigenetic regulation, which
underlies the diversity of the disease progression throughout the body system and across
different patients that share a near-identical genetic background, except those which have
inborn genetic mutations [16–19].
Zoonosis and reverse zoonosis infer a dynamic exchange of pathogens between
humans and animals, particularly domestic and wild vertebrates. This constitutes a major
challenge for both public health and animal health, and unites them into one ecological
health. The potential infection of SARS-CoV-2 in both wild and domestic animals is a
public health concern after the COVID-19 prevalence in human society [20,21]. This concern
emphasizes: (1) the identification of reservoir animal species that originally passed SARS-
CoV-2 to humans; and (2) potential risks of infected people passing the virus to animals,
particularly domestic species, to form an amplifying zoonotic cycle and exacerbate SARS-
CoV-2 evolution and cross-species transmission [20,21]. Studies have provided evidence
that domestic minks, cats, and dogs could be virally or serologically positive for SARS-
CoV-2 [20–28], as were several Bronx Zoo tigers [29]. Experimental animal inoculations
with human SARS-CoV-2 isolates demonstrated that ferrets, hamsters, domestic cats, and
some non-human primate species were susceptible to human SARS-CoV-2 strains; however,
pigs, alpacas, and (putatively) cattle are not [20–29]. Previously, we and several others
have proposed structural simulation models of ACE2 and the viral S-Receptor binding
domain (S-RBD) to predict SARS-CoV-2 susceptibility across representative vertebrates,
especially major domestic and wild mammalian species [30–33]. The structural affinity
between ACE2 and S-RBD plays a primary role in the viral attachment and accessibility in
cells, and the specific early cellular responses that regulate ACE2 expression and signal
early immune responses determine the host susceptibility to the virus [34–40]. We propose
an integrative model, which incorporates both ACE2-RBD structural affinity (primarily
determined by cross-species genetic difference) and epigenetic regulation of key genes
during the early phase of the virus-host interaction, to predict host COVID-19 susceptibility
and disease progression [30–33].
Among the core host factors that determine COVID-19 susceptibility and early dis-
ease progression, angiotensin-converting enzyme 2 (ACE2) and interleukin (IL)-6 were
focused upon because of their critical roles directly involved in viral infection and host im-
munopathies [41–45]. In SARS-CoV-2 pathogenesis, ACE2 serves as the primary receptors
for cell attachment and entry [42,43]. Several groups have reported that SARS-CoV-2 exerts
higher receptor affinity to human ACE2 than other coronaviruses, which may contribute
to the high-contagiousness and rapid spread of SARS-CoV-2 in humans [42,43]. Being a
key enzyme in the body’s renin–angiotensin–aldosterone system (RAAS), ACE2 catalyzes
angiotensinogen (AGT) to produce the active forms of hormonal angiotensin (Ang) 1–9,
which directly regulate the blood volume/pressure, body fluid balance, sodium and water
retention, as well as co-opt multiple effects on inflammation, apoptosis, and generation of
reactive oxygen species (ROS) [43–45]. In this regard, not only do the virus direct binding
and functional impairment of ACE2 enzymatic function, but also epigenetic regulation of
ACE2 expression in various tissues/conditions, serve as a physio-pathological mechanism
underlying the COVID-19 disease complex, and further relate to blood clotting, aneurisms
and chilblains in infant patients [43–46].
SARS-CoV-2 seizes ACE2 for cell entry, which can be followed by a cytokine-related
syndrome, namely acute respiratory distress syndrome (ARDS). Plausibly, the occupancy
of the ACE2 catalytic domain by the viral spike protein (S) blocks AGT activation into
Ang1–9 and leads to the accumulation of Ang2 in the serum [43–46]. Circulatory increase
in Ang2 induces inflammatory cytokines, including TNF-α, IL-6, and soluble IL-6 receptor
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α (sIL-6Rα) in pneumocytes and macrophages, through binding Ang1-receptor (AT1R)
and activating disintegrin- and metalloprotease 17 (ADAM17)-mediated cascade [41–46].
This process is followed by activation of the IL-6 amplifier (IL-6-AMP), which co-activates
NF-κB and transcription factor STAT3 to enhance inflammatory response and leads to
ARDS underlying COVID-19. Ang2-AT1R activation also induces pyroptosis, a highly
inflammatory form of programmed cell death accompanying cytotoxicity caused by viral
infections [41,45,46]. Aggregately, SARS-CoV-2 itself also activates NF-κB via various
pattern recognition receptors (PPRs) [33–40]. Therefore, IL-6 and IL-6 AMP are biomarkers
of hyperactivation of inflammatory machinery exacerbated by ACE2 blocking and viral
infection, which represent key cytokines in deciphering cytokine-related syndrome and
disease progression of COVID-19 [41,45,46].
The expression of ACE2 is inter-regulated by multiple physio-pathological factors,
including intracellular pathogenic infection, pre-existing inflammatory condition from co-
morbidities, and inflammatory cytokines including TNF and IFNs [41–46]. Several studies
have demonstrated that human ACE2 gene behaved like an interferon-stimulated gene
(ISG) and was stimulated by viral infection and IFN treatment; however, mouse Ace2 gene
was not [47–49]. Canonical ISGs describe over a thousand cellular genes that are induced
by IFN simulation via the IFN-JAK-STAT signaling axis [50]. These canonical ISGs are
mainly induced by type I and type III IFNs but overlap with those upregulated by type II
IFN (i.e., IFN-γ) [47–50]. These ISGs comprise a front line of antiviral immunity to restrict
virus spreading from the initial infection sites [50]. However, based on gene evolution
and epigenetic analyses, ACE2 may not be a member of these classical antiviral ISGs, and
more likely belongs to the non-canonical ISGs (non-ISGs) such as IL-6 (a.k.a. IFN-β2 in
humans) [47–51]. These non-ISGs are primed under a pre-inflammatory condition and stim-
ulated by IFN or IFN plus TNF through an epigenetic cascade involving positive histone
modification (mainly H3K4me3 and H3K27ac) to increase chromatin accessibility for bind-
ing by transcription factors (including PU.1, IRFs, and NF-κB) and culminating in non-ISGs
expression (Figure 1) [51–54]. To confirm that, we conducted cross-species comparative
analysis between IL-6 and ACE2 genes. First, annotation of ENCODE epigenetic datasets
discovered similarity of H3K4me3 and H3K27ac markers between IL-6 and ACE2 gene pro-
moters in both humans and mice; however, significantly higher Z-scores and enrichment of
H3K4me3 and H3K27ac in human IL-6 and ACE2 genes were detected than in their mouse
orthologs, respectively [55]. Secondly, detection of cis-regulatory elements (CREs) that bind
core transcription factors of non-ISGs, including PU.1, IRFs, and NF-κB, in ACE2 and IL-6
gene proximal promoter regions across 25 representative animal species [30,56]. Thirdly,
we found that the evolutionary increase in ACE2, and especially the IL-6 gene response
to inflammatory and IFN signaling may serve as an epigenetic marker for COVID-19
susceptibility in some animal species, including humans. Finally, using our non-biased
RNA-Seq data, we further categorized more non-ISGs that resemble the expression pattern
of either IL-6 or ACE2 [57]. Notably, we detected two ACE2 isoforms, which differ in both
proximal promoters and coding regions, in some livestock species including pigs, dogs,
and cattle [30]. In pigs, the ACE2 short isoform (ACE2S) has an expression pattern more
similar to IL-6 than the long isoform (ACE2L). Collectively, our findings characterize ACE2
and IL-6 genes as non-ISGs responding differently to inflammatory and IFN signaling, and
their epigenetic properties may serve as biomarkers to predict COVID-19 susceptibility in
vertebrates longitudinally and partially explain COVID-19 inequality in people of different
subgroups [20,30–33].




Figure 1. Schematic of epigenetic regulation and interferon (IFN) signaling to coordinate induction of non-canonical IFN-
stimulated genes (non-ISGs). Stimulation of lung macrophages and epithelial cells with tumor necrosis factor (TNF) in-
duces transient expression of TNF-target genes encoding inflammatory mediators, such as IL6 and TNF, followed by an 
insensitive state in which signaling responses to TLR ligands are strongly suppressed, and chromatin is not activated 
(depicted by a grey shade). This transient suppression state can be activated by a co-stimulation with TNF plus IFN-α and 
results in an increase in positive histone markers (mostly H3K4me3 and H3K27ac) and chromatin accessibility, which 
further coordinate binding of IRFs and NF-κB transcription factors and lead to non-ISG marker gene (such as IL-6) expres-
sion. Many inflammatory genes, including angiotensin converting enzyme 2 (ACE2), can be among these genes, which 
are bookmarked with primed chromatin and subsequently exhibit a robust transcriptional response even to very weak 
proximal TLR-induced signals, which may comprise a critical factor in the exacerbation of pulmonary inflammatory and 
COVID-19 syndrome. Adapted and redrawn from Barrat et al. (2019) [51]. Abbreviations: ac, acetyl; me, methylation; Pol, 
polymerase; PU.1, transcription factor binding to the PU-box, a.k.a SPI1; Non-ISG, non-canonical interferon stimulated 
genes; GTF, sTF, or TF, general (G), tissue-specific (s) transcription factor (TF); TLR, toll-like receptor; TSS, transcription 
start site. 
2. Materials and Methods 
2.1. Annotation of ENCODE Epigenetic Datasets 
The profile of epigenetic markers relevant to histone positive modification, mainly 
H3K4me3 and H3K27ac, were searched using the gene symbols through the ENCODE 
public domain at https://www.encodeproject.org/ under the default condition [55]. The 
ENCODE datasets for generating the epigenetic results include those mainly based on 
Chip-Seq and ATAC-Seq from 839 and 157 cell/tissue types of humans and mice, respec-
tively. The Max Z-Scores and locations of the histone markers on the gene promoter re-
gions were then curated under a permission for academic users, and manually diagramed. 
Figure 1. Schematic of epigenetic regulation and interferon (IFN) signaling to coordinate induction of non-canonical
IFN-stimulated genes (non-ISGs). Stimulation of lung macrophages and epithelial cells with tumor necrosis factor (TNF)
induces transient expression of TNF-target genes encoding inflammatory mediators, such as IL6 and TNF, followed by
an insensitiv state in which signaling responses to TLR lig nds re strongly suppressed, and chromatin is n t activated
( epicted by a grey shade). This transient suppression state can be activated by a co-stimulation with plus IFN-α and
results in an increase in positive histone markers (mostly H3K4me3 and H3K27ac) and chromatin accessibility, which furth r
coordinate binding of IRFs and NF-κB transcription factors and lead to non-ISG marker gene (such as IL-6) expression.
Many inflammatory genes, including angiotensin converting enzyme 2 (ACE2), can be among these genes, which are
bookmarked with primed chromatin and subsequently exhibit a robust transcriptional response even to very weak proximal
TLR-induced signals, which may comprise a critical factor in the exacerbation of pulmonary inflammatory and COVID-19
syndrome. Adapted and redrawn from Barrat et al. (2019) [51]. Abbreviations: ac, acetyl; me, methylation; Pol, polymerase;
PU.1, transcription factor binding to the PU-box, a.k.a SPI1; Non-ISG, non-canonical interferon stimulated genes; GTF, sTF,
or TF, general (G), tissue-specific (s) transcription factor (TF); TLR, toll-like receptor; TSS, tr scriptio start site.
2. Materials and Methods
2.1. Annotation of ENCODE Epigenetic Datasets
The profile of epigenetic markers relevant to histone positive modification, mainly
H3K4me3 and H3K27ac, were searched using the gene symbols through the ENCODE
public domain at https://www.encodeproject.org/ under the default condition [55]. The
ENCODE datasets for generating the epigenetic results include those mainly based on Chip-
Seq and ATAC-Seq from 839 and 157 cell/tissue types of humans and mice, respectively.
The Max Z-Scores and locations of the histone markers on the gene promoter regions were
then curated under a permission for academic users, and manually diagramed.
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2.2. Promoter Sequence Extraction and Alignment
The DNA sequences of the proximal promoters of analyzed genes were extracted
from NCBI Gene and relevant databases (https://www.ncbi.nlm.nih.gov/gene). Both
IL-6 and ACE2 genes and corresponding transcripts have been well annotated in most
representative vertebrate species. In most cases, the annotations were double verified
through the same Gene entries at Ensembl (https://www.ensembl.org). The protein and
DNA sequences were collected from all non-redundant transcript variants and further
verified for expression using relevant RNA-Seq data (NCBI GEO profiles) (Supplemen-
tal File S1). The proximal promoter region spanned ~2.5 kb before the predicted tran-
scription (or translation) start site (TSS). The protein and DNA sequences were aligned
using the multiple sequence alignment tools of ClustalW or Muscle through an EMBL-
EBI port (https://www.ebi.ac.uk/). Other sequence management was conducted us-
ing programs at the Sequence Manipulation Suite (http://www.bioinformatics.org). Se-
quence alignments were visualized using Jalview (http://www.jalview.org) and MEGAx
(https://www.megasoftware.net). Sequence similarity calculations and plotting were con-
ducted using SDT1.2 (http://web.cbio.uct.ac.za/~brejnev). Other than those indicated, all
programs were run with default parameters [30].
2.3. Examining Transcription Factor Binding Sites in the Gene Promoters and PWM Scoring
We used two programs/databases to confirm each other for the major CRE predic-
tions. The regulatory elements (and corresponding binding factors) in the ~2.5 kb proximal
promoter regions were examined against both the human/animal TFD Database using a
program Nsite (Version 5.2013, at http://www.softberry.com). The mean position weight
matrix (PWM) of key cis-elements in the proximal promoters were calculated using PWM
tools through https://ccg.epfl.ch/cgi-bin/pwmtools, and the binding motif matrices of
examined TFs were extracted from MEME-derived HOCOMOCOv11 TF collection affil-
iated with the PWM tools [56]. The species-specific CRE sequences were then extracted
from each promoter sequence for alignments, as shown in Figure 3.
2.4. Phylogenic Analysis and Topological Comparison
Evolutionary analyses were conducted in MEGA X as described [30]. The evolutionary
history was inferred by using the maximum likelihood method and Tamura–Nei model.
Initial tree(s) for the heuristic search were obtained automatically by applying Neighbor-
Join and BioNJ algorithms to a matrix of pairwise distances estimated using the Tamura–Nei
model, and then selecting the topology with superior log likelihood value. For topological
comparison between phylogenic trees generated using IL-6 and ACE2 gene proximal
promoters, the phylogenies of Newick strings were generated using the MEGA program,
and topological comparison between the Newick trees was performed with Compare2Trees
at (http://www.mas.ncl.ac.uk/~ntmwn/compare2trees) to obtain the overall topological
scores. Other than those indicated, all programs were run with default parameters as the
programs suggested.
2.5. RNA-Seq and Data Analysis
During cross-species annotation of ACE2 and IL-6 genes, RNA-Seq datasets that
are affiliated to NCBI gene entries (such as BioProjects PRJEB4337 and PRJNA66167 for
humans and mice genes) were used to verify the gene expression per RNA-Seq exon/intron
coverage analyses. The detailed records for NCBI RNA-Seq data analyses are provided as
in the Supplementary File S1. For expression confirmation, several sets of RNA-Seq data
from NCBI Gene databases, and one of ours generated from porcine alveolar macrophages
(BioProject with an accession number of SRP033717), were analyzed for categorizing ISGs
and non-ISGs accordingly to the expression patterns of IL-6 and ACE2 genes. Significantly
and differentially expressed genes (DEGs) between two treatments were described using
an edgeR package and visualized using bar charts (RPKM) or heatmaps (Log2 fold ratio)
as previously described [57].
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3. Results and Discussion
3.1. Epigenetic Processes in Induction of Non-Canonical IFN-Stimulated Genes (Non-ISGs)
Studied mostly in humans and mice, the hundreds of classical ISGs, such as ISG15 and
IRF1, contain the main IFN-responsive CREs, including IFN-stimulated regulatory element
(ISRE) and γ-activated sequence (GAS), in their promoter regions [47,50]. The tripartite
IFN-stimulated gene factor 3 (ISGF3), which is composed of three transcription factors
including STAT1, STAT2 and IRF9, is activated downstream of the IFN-JAK-STAT signaling
axis to bind ISREs and stimulate canonical ISG expression [47,50]. In addition to this clas-
sical axis to induce ISGs, IFNs also co-opt multiple non-canonical signaling pathways to
activate these ISGs or other corresponding genes together through various alterative mech-
anisms [51–54]. These non-canonical IFN signaling pathways involve extensive crosstalk
between the signaling pathways mediated by various cellular pathogen pattern-recognition
receptors (PRRs) and inflammatory cytokines, notably IL-1, IL-6, and TNF [51–54]. The
non-canonical signaling pathways not only diversify mechanisms for inducing ISGs, but
also extend the spectrum of IFN-responsive genes, indicating a multifunctional property
of IFNs in antiviral and immuno-physiological regulation [50–54]. Studies have shown
that human IL-6 and ACE2 are two candidates for these non-ISGs [47–51]. Figure 1 shows
the current understanding of the gene activation cascade of human IL-6 (and plausibly
ACE2) genes as an example of non-ISGs, whose IFN-inductive property and systemic role
have been recognized as underlying multiple inflammatory comorbidities [51,54]. In brief,
stimulation of epithelial cells and tissue macrophages by early pro-inflammatory signaling
of TNF induces transient expression of TNF-target genes encoding inflammatory mediators,
such as IL6 and TNF. This is followed by a transient state that is insensitive to further
inflammatory signaling from TLR activation, and thus relevant chromatin-containing non-
ISGs are not activated (depicted by a grey shade in Figure 1). This transient suppression
state, however, can be activated by a co-stimulation with TNF plus IFN-α, resulting in an
increase in positive histone marks (H3K4me3 and H3K27ac) and chromatin accessibility
of the gene promoter regions, which sequentially recruit the binding of corresponding
transcription factors including IRFs and NF-κB to activate non-ISG expression [51,54].
Besides IL-6, many tunable ISGs, including human ACE2 as has been demonstrated, show
sustainable responses to IFN and pathogenic inflammatory signaling, and share expres-
sion patterns involving epigenetic sensation and synergistic IFN-induction as depicted for
non-ISGs (Figure 1) [47–54]. However, the cross-species evolutionary characterization of
non-ISGs has not been studied. Using IL-6 and ACE2 as examples, extensive epigenetic and
expression analyses were performed in this study to determine their epigenetic evolution
and potential role as biomarkers to predict the susceptibility and disease progression of
COVID-19.
3.2. Determine Species-Specific Positive Histone Marks in Human and Mouse IL-6 and ACE2
Gene Promoters
Epigenetic positive histone modification in a certain chromatin region, mainly in-
cluding histone H3 with tri-methylation at the 4-lysine residue (H3K4me3) or with the
acetylation at the 27-lysine residue (H3K27ac) here, is associated with a higher activation
status of adjacent gene transcription, thus defined as positive epigenetic marks enhancing
relevant gene expression. The enrichment of H3K4me3 and H3K27ac defines one epige-
netic feature of non-ISGs post activation [51–55]. Through annotation of Chip-Seq and
ATAC-Seq datasets from 839 and 157 cell/tissue types of humans and mice through EN-
CODE (https://www.encodeproject.org/) [55], we detected significant and comparative
existence of H3K4me3 and H3K27ac markers between IL-6 and ACE2 gene promoters in
various humans and mouse samples (Figure 2). However, higher Z-scores and enrichment
of H3K4me3 and H3K27ac were found in human IL-6 and ACE2 genes (Figure 2A,B) than
their mouse orthologs (Figure 2C,D). In both distal and proximal regions of the ACE2 gene
promoters, the human gene (Figure 2A) was marked by 2–3-fold more positive histone
modifications than the mouse ortholog, indicating higher activation and transcription
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activity of human IL-6 and ACE2 genes under similar conditions. Notably, human IL-6 is
a short gene located distantly from other coding genes and might be correlated to higher
histone marks (esp. H3K27Ac) relevant to distal super enhancers. By contrast, human
ACE2 gene is a relatively long gene surrounded by other genes, and its major promoter
is compacted in a more proximal region and has a limited H3K27Ac marks spanning the
2000–5000 bp distal region. Because these findings are extracted from the extensive datasets
representing systemic sample types, it is convincing that typical epigenetic positive histone
modifications, H3K4me3 and H3K27ac, are significantly associated with the promoter
regions of ACE2 as with IL-6 genes. Specifically, IL-6 genes were shown to have more
histone modifications around their proximal promoter regions than ACE2 genes, which
had more in a very distal region (>20 kb). There were higher Z-scores and enrichment
of these positive histone markers in the human genes than their mouse orthologs, indi-
cating evolutionary and probably species-specific manners of epigenetic regulation of
these non-ISGs [51,54]. This epigenetic difference of key non-ISGs might contribute to
disease susceptibility and progression when animals of different species are exposed to
same pathogenic pressure.




Figure 2. Profiling of positive histone markers (H3K4me3 and H3K27ac) indicating chromatin accessibility of RNA poly-
merase II adjacent to human and mouse ACE2 and IL-6 gene bodies, respectively. Annotation of ENCODE epigenetic 
datasets (Chip-Seq and ATAC-Seq from 839 and 157 cell/tissue types of humans and mice, respectively, from 
https://www.encodeproject.org/). Comparative existence of H3K4me3 and H3K27ac markers was detected between IL-6 
and ACE2 gene promoters in either humans (A,B) and mice (C,D); however, higher Z-scores and enrichment of H3K4me3 
and H3K27ac were found in human IL-6 and ACE2 genes (A,B) than their orthologs in mice (C,D). Distal, >2000 bp before 
the transcription start sites (TSS), and proximal promoter within 2000 bp before the TSS. Datasets with Z-score higher than 
the overall average are shaded with oval shapes. 
Figure 2. Profiling of positive istone markers (H3K4me3 and H3K27ac) indicating chromatin accessibility of RNA
polymerase II adjacent to human and mouse ACE2 and IL-6 gene bodies, respectively. Annotation of ENCODE epigenetic
datasets (Chip-Seq and ATAC-Seq from 839 and 157 cell/tissue types of humans and mice, respectively, from https:
//www.encodeproject.org/). Comparative existence of H3K4me3 and H3K27ac markers was d tected between IL-6 and
ACE2 gene promoters in either humans (A,B) and mice (C,D); however, higher Z-scores and enrichment of H3K4me3 and
H3K27ac were found in human IL-6 and ACE2 genes (A,B) than their orthologs in mice (C,D). Distal, >2000 bp before the
transcription start sites (TSS), and proximal promoter within 2000 bp before the TSS. Datasets with Z-score higher than the
overall average are shaded with oval shapes.
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3.3. Cross-Species Comparison of Key Cis-Regulatory Elements (CREs) That Mark Non-ISG
Regulation in IL-6 and ACE2 Genes
After determination of positive histone markers along the IL-6 and ACE2 gene bodies,
we examined the existence of cis-regulatory elements (CREs) that interact with typical non-
ISGs transcription factors, including PU.1 (a.k.a. SPI1), IRFs, and NF-κB1/2 in the promoter
regions of IL-6 and ACE2 gene orthologs [50–56]. We extracted the primary promoter
sequences from IL-6 and ACE2 genes from 25 representative vertebrate species, which
contained ten previously validated SARS-CoV-2-susceptible species and other naturally
unsusceptible species based on collected evidence [26–30]. As shown in Figure 3, all three
types of CREs (i.e., PU.1, IRFs, and NF-κB) that mark non-ISG expression were mapped for
cross-species existence in the promoter regions of both IL-6 and ACE2 genes. Significant
PWM scores (p < 0.0001) were determined for their CREs when each was compared with
the corresponding human CRE matrix (Figure 3A–C) [56]. ACE2 genes had a generally
lower PWM score for these CREs than those for IL-6 genes, in particular the PWM scores
for NF-κB2 CRE in ACE2 genes were at 2–8 Log2 units lower (Figure 3D). This indicates
that ACE2 genes were less responsive to non-canonical NF-κB signaling mediated by
NF-κB2 [58,59]. Because dysregulation of non-canonical NF-κB signaling contributes to
various autoimmune and inflammatory diseases, the differential role of ACE2 and IL-6 in
inflammatory immunopathies are worth further investigation [58,59]. Notably, only CRE
matrices to IRF1 are shown in Figure 3C; both ACE2 and IL-6 gene promoters actually
contain CREs binding IRF2-8 with high PWM scores, except for CREs interacting with IRF5
and IRF9 which had low PWM scores in most tested species (Figures 4 and 5). Because IRF9
is a key component of ISGF3 and binding to ISREs to activate canonical ISG expression,
this discovery evidently distinguishes ACE2 and IL-6 genes from the classical ISGs such
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responsiveness to non-canonical NF-κB2 signaling (Figure 5D). Studies have shown that
defects in non-canonical NF-κB2 signaling are associated with severe immune deficiencies,
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SPI1), (B) IRF1, and (C,D) NF-κB1/2 in the promoter regions of IL-6 and ACE2 gene orthologs from the representative two
SARS-CoV-2-unsusceptible species (pigs and mice) and seven susceptible species. All three types of CREs have comparable
Log2(mPWM) scores between ACE2 and IL-6 genes, except NF-κB2 that mediates non-canonical NF-κB response. (D) has a
significant lower mPWN score (2–6 Log2 units), indicating ACE2 genes are among different non-ISGs group other than IL-6.
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affiliated with the PWM tools. PWM, position weight matrix.
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Figure 4. Lack of ISRE/IRF9 binding site that respo signaling for ISG expression in analyzed IL-6 and ACE2
genes. Cross-species analysis of mean PWM (mPWM) scores of cis-regulatory elements (CREs) that bind ISRE/IRF9 in the
proximal promoter regions of IL-6 and ACE2 gene orthologs from the 25 representative vertebrate species. mPWM score is
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affiliated with the PWM tools. PWM, position weight matrix. Abbreviations: D-rerio, Danio rerio (Zebrafish); X_trapicalis,
Xenopus trapicalis; G_monkey, African Green Monkey; h-, human.
3.4. Epigenetic Evolution of Higher PWM Scores of Non-ISG’s Core CREs in ACE2 and Especially
IL-6 Gene Pro oters in COVID-19-Susceptible Species
As previously described, i addition to its core role in the physiological regulation
of blood volume/pressure and body fluid balance, the RAAS also critically affects in-
flammation, apoptosis, and other immune reactions. For instance, suppression of ACE2
increases Ang2 production to signal pro-inflammatory and apoptotic responses in affected
tissues [44–46]. When exacerbated by infection of an intracellular pathogen, such as SARS-
CoV-2 in COVID-19 cases, a high inflammatory form of programed cell death, known as
pyroptosis, is induced, accompanying massive production of pro-inflammatory cytokines
including IL-1, IL-6, TNF and CXCL10 [41,45,46]. Due to the potential clinical relevance to
these CREs in COVID-19, we perform d a comparative study to determine if the COVID-19
susceptible animal species obtai ed some epigenetic f atures in these core CREs in regu-
lation of IL-6 and ACE2 expression. Figure 6 compares the mPWM scores of these core
non-ISG CREs between two groups: know SARS-CoV-2-susceptible species [CoV2(+)] and
unsusceptible species [CoV2(−)]. Figure 6 shows that ACE2 and IL-6 genes from CoV2(+)
species contain CREs that have significantly higher mPWM scores. This indicates that,
in some vertebrate species, non-ISGs such as ACE2 and especially IL-6 genes evolve to
obtain high inductive propensity by inflammatory and IFN signaling [47–54]. Therefore, in
addition to the ACE2 structure and affinity to S-RBD, the epigenetic evolution for IL-6 and
ACE2 stimulation (reflected by higher mPWM scores), may serve as epigenetic biomarkers
(or triggers) for susceptibility predictions of COVID-19 and other ARDS longitudinally
across vertebrates and horizontally in subgroups of humans [30,47–54].
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(a.k.a. SPI1), (C) NF-κB1, (D) NF-κB2, and (E) IRFs (including IRF1-9, which show significant PWM scores with p < 0.0001)
in the proximal promote regions of IL-6 and ACE2 g ne orthologs from the 25 r presentative vertebrate species. All types
of CREs have comparable Log2(mPWM) scores between ACE2 and IL-6 genes, except NF-κB2 that mediates non-canonical
NF-κB response. (D) has a significant lower mPWN score (2–6 Log2 units), indicating ACE2 genes are among different non-
ISGs group other than IL-6. Canonical ISGs of human ISG15 and IRF1 are used as references. mPWM scores were calculated
using tools at https://ccg.epfl.ch/pwmtools/pwmscore.php with CRE matrices from MEME-derived HOCOMOCOv11 TF
collection affiliated with the PWM tools. PWM, position weight matrix. Other abbreviations are as in Figure 4.
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Figure 6. Cross-species correlation of epigenetically regulatory CREs, which associate with inflammatory and IFN signaling,
in IL-6 and ACE2 gene promoters as biomarkers for COVID-19 susceptibility. Mean PWM (mPWM) scores were generated
as described in previous figures, and compared between two groups of known COVID-19 susceptible species [CoV2(+)]
and unsusceptible species [CoV2(−)]. This shows that ACE2, and especially IL-6 genes, from CoV2(+) species contain the
CREs which have significantly higher mPWM scores, indicating that in some vertebrate species, non-ISGs such as ACE2
and especially IL-6 genes evolved to obtain high inductive propensity by inflammatory and IFN signaling, and may serve
as epigenetic biomarkers (or triggers) for susceptibility prediction of COVID-19 and other ARD syndrome. *, p < 0.05, and
**, p < 0.01 and ∆Log2(mPWM) > 1; n = 10, compared between the CoV(+) and CoV(−) groups. Abbreviation: H_Bat, great
horseshoe bat; other abbreviations are as in Figure 4.
3.5. Overall Comparison of Phylogenic Topologies between IL-6 and ACE2 Gene Promoter
Sequences
In addition to focusing on epigenetic analysis of these non-ISG CREs, we also con-
ducted cross-species comparisons of phylogenic topology between the full proximal pro-
moter sequences of IL-6 and ACE2 genes. Overall, the topology of the phylogenies of
IL-6 and ACE2 gene promoters are similar, with a comparative topological score of 86.5%
(Figure 7). Sharing a root of low vertebrates (D. rerio and/or X. tropicalis), the CoV2(+)
species were distributed within the clades containing primates, carnivores, and glires. In
contrast, all the ruminant promoters were clustered into a most phylogenically distant clade
and associated with no CoV2(+) species (Figure 7). Comparison of the two phylogenies
in detail showed that the major difference came from the location of the chicken, rabbit,
guinea pig, and pig. In the IL-6 promoter phylogeny (Figure 7, left panel), chicken IL-6
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promoter seems to derive rodent IL-6 gene promoters after evolution from the fish and
frog; in the ACE2 promoter phylogeny (Figure 7, right panel), however, the chicken ACE2
promoter serves as a root leaf with the zebrafish. The largest difference is between the
phylogenic positions of IL-6 and ACE2 gene promoters for pigs and guinea pigs. Whereas
in the IL-6 promoter phylogeny, the porcine one sisters to those of the alpaca and horse,
within the carnivore clade that contains most of the validated CoV2(+) species in addition
to the primate clade, the porcine ACE2 gene promoter was next to the ruminant clade
that has no CoV2(+) species identified so far [20–29]. Guinea pig as a rodent species has
its IL-6 promoter surprisingly within the primate clade, but its ACE2 promoter appears
more primitive and shares the clade with the frog. Given that the primate and carnivore
clades contain most identified CoV2(+) species, if pig and guinea pig are proven to be
CoV2(+) species, the IL-6 promoter phylogeny may better correlate to CoV2(+) prediction;
otherwise, the ACE2 promoter phylogeny correlates better. The rabbit and otter, which
occupy similar positions in both IL-6 and ACE2 promoter phylogenies, may have a high
potential to be CoV2(+) and COVID-19-susceptible based on this and previous studies,
which used epigenetic and structural models, respectively [30–33]. In this regard, pigs
and guinea pigs may serve as symbol species to estimate the epigenetic role of non-ISGs
in CoV2(+) prediction. No study has tested CoV2/COVID-19 susceptibility in guinea
pigs, but studies in pigs concluded that the species was unsusceptible [20]. This may
indicate that the overall epigenetic feature of ACE2 genes better relates to CoV2(+) status
in some mammalian species. However, the study of key CRE scores of non-ISGs in Figure
6 indicates that IL-6 gene CRE scores have a higher correlation when compared between
the CoV2(+) and CoV2(−) species. This may reflect an etiological fact that CoV2(+) is
necessary but not sufficient for COVID-19 progression; and the latter is indeed dependent
on the host immune reaction, particularly the early ISGs and non-ISG responses studied
here [51,54]. In that regard, epigenetic evolution/regulation of ACE2 and IL-6 genes may
signify two layers of COVID-19 progression, i.e., ACE2 is better for CoV2(+) and IL-6 is
better for downstream COVID-19 symptoms [51,54,58,59].
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were conducted in MEGA X. The evolutionary history as inferred by using the maximum likelihood method and
Tamura–Nei model. The tree with the highest log likelihood (−52,755.39) is shown. The percentage of trees in which
the associated taxa clustered together is shown next to the branches. Initial tree(s) for the heuristic search were obtained
automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated using the
Tamura–Nei model, and then s lecti the topology with superior log lik lihood value. For topological compa ison
betwe n phylogenic trees generated using IL-6 and ACE2 gene proximal promoters, the phylogenies of Newick trings
were generated using MEGA, and topological comparison between the Newick trees was performed with Compare2Trees at
(http://www.mas.ncl.ac.uk/~ntmwn/compare2trees) to obtain the overall topological scores. Orange circle: COVID-19
susceptible species. Arrows: other tentative marker species to determine which group (IL-6 or ACE2) of non-ISGs are more
determined for COVID-19 susceptibility. Abbreviations are as in Figure 4.
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3.6. Non-Bias Transcriptome-Based Categorization of Non-ISGs That Resemble to the Inductive
Pattern to IL-6 or ACE2 Genes
Compared with canonical ISGs, studies of epigenetic regulation and expression of non-
ISGs have just started accompanying our understanding of their role in some autoimmune
and inflammatory diseases [50–54]. Although some non-canonical signaling pathways,
that are independent of the canonical IFN-JAK-ISGF3 axis, play a role in ISG induction,
the classification criteria of non-ISGs are not established [50–54]. Using IL-6 and ACE2
genes as examples of non-ISGs, the disparity of their cross-response to inflammatory and
IFN signaling could be one way to classify them as IL-6-like or ACE2-like groups. We
therefore analyzed a non-biased transcriptome (RNA-Seq) dataset from porcine alveolar
macrophages treated with different stimuli and infected with a porcine arterivirus, a
respiratory virus belonging to Nidovirales with coronaviruses [57]. We chose to use
porcine transcriptome data because of the species-focus of our projects and the anatomical
and physiological resemblance between pigs and humans [57]. Figure 8 presents the IL-
6-like and ACE2-like groups, which were categorized based on their responsive patterns
to liposaccharide (LPS) and two types of IFNs (i.e., IFN-α or type I and type II IFN-γ) at
the early phase of 5 h post-treatment/infection [57]. These clustered IFN responsive genes
were mainly from the RAAS, TNF, IL-6, chemokine superfamilies. For the IL-6 non-ISG
group, all of these genes showed robust stimulation by LPS as well as a weaker response to
both IFNs (Figure 8A). In contrast, the ACE2-group genes were insensitive to LPS, but were
upregulated significantly by both types of IFNs (Figure 8B). Compared with the canonical
group of ISGs (Figure 8C), which shows the highest response to the type I IFN-α, the IL-6
group had the least increase upon IFN-α and a similar stimulation by IFN-γ as for ISGs;
and the ACE2 group showed a mid-response to IFN-α but highest to IFN-γ (Figure 8A–D).
Figure 8D statistically demonstrates the stimulatory difference among three groups of IFN-
responsive genes: (1) for ISGs: IFN-α > IFN-γ > LPS with a higher background expression
in PBS, IL-4, and IL-10 treatments; (2) for IL-6-like non-ISGs: LPS > IFN-γ > IFN-α with the
lowest background expression; and (3) for ACE2-like non-ISGs: IFN-γ > IFN-α > LPS with
a mid-background expression. Therefore, our classification of ISGs and non-ISGs represents
a complete scenario of gene response levels (i.e., at low, mid, and high levels of responses
to LPS and two types of IFNs) to complement each other per their responsive propensity
to LPS, IFN-γ, and IFN-α. As previously described, most ISGs, especially non-ISGs, are
inter-regulated through multiple canonical and non-canonical signaling pathways. The
cross-talking of signaling pathways mediated by different types of IFNs and inflammatory
cytokines is dynamic to form into an intricate regulatory network underlying animal
immunity to determine disease pathogenesis in various situations [50–54]. Therefore, with
the functional extension of physiological genes such as AGT and ACE2, the new discovery
of species-dependent response to viral infections and IFN stimulation posits them as
immunogenetic factors critical to determining COVID-19 disease progression in addition
to its role as a major virus receptor [44–49]. Notably, several ACE2 isoforms have been
identified in humans and several major livestock species [30,60,61]. Our transcriptome
analysis also picked up one short porcine ACE2 isoform (ACE2S)—its expression pattern is
actually more like IL-6 non-ISGs than the consensus ACE2 longer isoform (ACE2L) [30]. In
addition to ACE2, the AGT gene of the RAAS also showed a non-ISG property similar to
ACE2 (Figure 8A,B). Collectively, transcriptomic annotation afforded us to cluster tentative
non-ISGs that share expression patterns similar to IL-6 or ACE2 genes. Interestingly, most
of them belong to IL-6, TNF, and chemokine superfamilies, whose roles in regulation of
autoimmune and inflammatory diseases, as well as in COVID-19 progression, warrant
further investigation.
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grouped using heatmaps according to their inductive expression patterns similar to: (A) IL-6, (B) ACE2; (C) Examples of 
canonical ISGs as reference; (D) Averaged transcriptomic expression levels (normalized at reads per kilobase of transcript 
per million mapped reads, RPKM) of the grouped ISGs or non-ISGs above. Indicated by arrows, pigs have two ACE2 
isoforms, namely ACE2L and ACE2S, which have different expression patterns; ACE2S similar to IL-6 showed to be less 
responsive to IFN-α but highly responsive to LPS and IFN-γ. In contrast, ACE2L and another key gene, AGT, in RAS were 
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6 group (A). 
4. Conclusions 
Figure 9 depicts the working summary of this study for epigenetic evolution and 
regulation of IL-6 and ACE2 as non-ISGs, indicating their potentials as biomarkers for 
inflammatory syndrome underlying pathogenic viral infection such as of COVID-19. Non-
ISGs such as those categorized by resemblance to IL-6 and ACE2 genes were sequentially 
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Figure 8. Genome-wide categorizing non-ISGs based on the similarity of inductive pattern to IL-6 and ACE2 genes. The
no -biased genome-wide transcripto i e erated using an RNA-Seq procedure in porcine lung macrophages
stimulated with each a ti ti sti ulator of IL-4, IL-10, LPS, IFN-α or IFN-γ at 20 ng/mL and infected by porcine
arterivirus virus for 5 h, using an Illumina procedure as previously described [57]. Significantly differentially expressed
genes (DEGs) in the renin–angiotensin system (RAS), interleukin (IL)-6, TNF, and chemokine super-families were annotated
and grouped using heatmaps according to their inductive expression patterns similar to: (A) IL-6, (B) ACE2; (C) Examples
of canonical ISGs as reference; (D) Averaged transcriptomic expression levels (normalized at reads per kilobase of transcript
per million mapped reads, RPKM) of the group d ISGs or non-ISGs above. Indicated by arr ws, pigs have two ACE2
isoforms, namely ACE2L and ACE2S, which have different expression patterns; ACE2S similar to IL-6 showed to be less
responsive to IFN-α but highly responsive to LPS and IFN-γ. In contrast, ACE2L and another key gene, AGT, in RAS were
categorized together with other non-ISGs (B), which is more like the expression pattern of canonical ISGs (C) than the IL-6
group (A).
4. Conclusi ns
Figure 9 depicts the working summary of this study for epigenetic evolution and
regulation of IL-6 and ACE2 as non-ISGs, indicating their potentials as biomarkers for
inflammatory syndrome underlying pathogenic viral infection such as of COVID-19. Non-
ISGs such as those categorized by resemblance to IL-6 and ACE2 genes were sequentially
regulated by TNF, IFN and TLR signaling, which modify chromatin accessibility through
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activating histone modification and recruitment of transcription factors including PU.1,
IRF, and NF-κB binding on the promoter regions of these non-ISGs. In turn, it will amplify
the inflammatory loop through IL-6-mediated response and inducing more ACE2 expres-
sion, which collectively contributes to the occurrence of respiratory and inflammatory
syndromes as in COVID-19. Therefore, high expression of non-ISGs such as IL-6 and ACE2
could be biomarkers for the exacerbation of inflammation underlying some viral infections,
especially those such as SARS-CoV-2, which dysregulates the physiological function of
ACE2 in the RAAS-centric body systems. In addition, the cross-species epigenetic evo-
lution of these key physio-pathological genes may provide a key to decipher molecular
mechanisms underlying species-specific susceptibility to COVID-19 from the host side.
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Figure 9. Working summary for IL-6 and ACE2 as non-ISGs biomarkers and contribution to COVID-19 susceptibility.
Epigenetic regulation of non-ISGs such as IL-6 and ACE2 was sequentially regulated by TNF, IFN and TLR signaling, which
modify chromatin accessibility through activating histone modification and recruitment of transcription factors including
PU.1, IRF and NF-κB binding on promoter regions of IL-6 and ACE2 genes. In turn, it will amplify inflammatory loops
through IL-6-mediated responses and induce more ACE2 expression, which collectively contributes to the occurrence of
respiratory distress syndrome, as in COVID-19. Therefore, high expression of non-ISGs such as IL-6 and ACE2 could be
biomarkers to determine COVID-19 susceptibility and disease development in different animal species. Abbreviations:
non-ISG, non-canonical interferon stimulated genes; GTF, sTF, or TF, general (G), tissue-specific (s) transcription factor (TF);
TLR, toll-like receptor; TSS, transcription start site.
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